Literature DB >> 7448106

Lignocaine and indocyanine green kinetics in patients following myocardial infarction.

N D Bax, G T Tucker, H F Woods.   

Abstract

1. Blood clearances of lignocaine and indocyanine green together with indocyanine green half-lives were measured in 17 post-myocardial infarct patients (one patient was studied twice) between 8 h and 36 h after starting intravenous lignocaine infusions for the treatment of cardiac arrhythmias. 2. Mean +/- s.d. values of lignocaine clearance (ml min-1 kg-1) were higher in patients without heart failure (11.8 +/- 2.6, n = 9) than in those with heart failure (7.2 +/- 1.9, n = 9) (P < 0002). 3. Clearances of lignocaine and indocyanine green were not correlated but lignocaine clearance was directly related to the reciprocal of indocyanine green half-life (rs = 0.67, P < 0.01). 4. In eight patients who received both lignocaine and indocyanine green and in a further five patients received only lignocaine and whose lignocaine infusions lasted 24h or more, a 25% rise in lignocaine concentrations was observed between 8-12h and 24-28h. 5. The mean +/- s.d. post-infusion terminal half-life of lignocaine in four patients whose lignocaine infusions lasted 30h or longer was 7.2 +/- 2.1 h. 6. Heart failure was associated with greater changes in lignocaine kinetics than in indocyanine green kinetics. 72% of the variance between observed and predicted lignocaine clearances could be accounted for by multiple linear regression analysis incorporating indocyanine green half-life and the presence or absence of heart failure. Indocyanine green half-life contributed only 17% of the variance indicating that by itself it is of limited value in predicting lignocaine requirements. 7. Lignocaine kinetics during and after prolonged intravenous infusion were not predicted by data obtained after intravenous bolus injection. 8. A lowering of lignocaine dosage may be clinically desirable in the presence of heart failure and if an infusion lasts longer than 24 h.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7448106      PMCID: PMC1430088          DOI: 10.1111/j.1365-2125.1980.tb01771.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Logical approach to lignocaine therapy.

Authors:  C Aps; J A Bell; B S Jenkins; P A Poole-Wilson; F Reynolds
Journal:  Br Med J       Date:  1976-01-03

2.  GLC analysis of lidocaine in blood using an alkaline flame-ionization detector.

Authors:  T R Irgens; W M Henderson; W H Shelver
Journal:  J Pharm Sci       Date:  1976-04       Impact factor: 3.534

3.  Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients.

Authors:  K I Lie; H J Wellens; F J van Capelle; D Durrer
Journal:  N Engl J Med       Date:  1974-12-19       Impact factor: 91.245

4.  Evaluation of lidocaine resistance in man using intermittent large-dose infusion techniques.

Authors:  E L Alderman; R E Kerber; D C Harrison
Journal:  Am J Cardiol       Date:  1974-09       Impact factor: 2.778

5.  Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.

Authors:  P D Thomson; K L Melmon; J A Richardson; K Cohn; W Steinbrunn; R Cudihee; M Rowland
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

6.  Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man.

Authors:  R E Stenson; R T Constantino; D C Harrison
Journal:  Circulation       Date:  1971-02       Impact factor: 29.690

7.  Lidocaine disposition kinetics in monkey and man. II. Effects of hemorrhage and sympathomimetic drug administration.

Authors:  N Benowitz; R P Forsyth; K L Melmon; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

8.  Diagnosis of placenta praevia by photoscanning with albumin labeled with technetium Tc 99m.

Authors:  W B Nelp; S M Larson
Journal:  JAMA       Date:  1967-04-10       Impact factor: 56.272

9.  Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.

Authors:  L F Prescott; K K Adjepon-Yamoah; R G Talbot
Journal:  Br Med J       Date:  1976-04-17

10.  Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green.

Authors:  R L Williams; T F Blaschke; P J Meffin; K L Melmon; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

View more
  15 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 2.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 3.  The Smith Kline & French lecture 1987. Clinical pharmacology and the art of bespoke prescribing.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

4.  Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine.

Authors:  G T Tucker; N D Bax; M S Lennard; S Al-Asady; H S Bharaj; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

5.  Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility.

Authors:  C S Deacon; M S Lennard; N D Bax; H F Woods; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 7.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

8.  The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition.

Authors:  N D Bax; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

9.  Rapid prediction of individual dosage requirements for lignocaine.

Authors:  S Vozeh; M Berger; M Wenk; R Ritz; F Follath
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

10.  Time-dependent kinetics of lignocaine in the isolated perfused rat liver.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  J Pharmacokinet Biopharm       Date:  1983-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.